← Back to Search

Treatment for Alzheimer's Disease (LIFE-DSR Trial)

N/A
Waitlist Available
Research Sponsored by LuMind IDSC Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights
No Placebo-Only Group

Summary

The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Behavioral Measure
Cognitive Measure
Functional Measure
+1 more
Secondary study objectives
Exploratory Outcome Measure Novel multi-domain instrument for AD-DS development
Exploratory Outcome Measure Potential Screening Measures
Exploratory Outcome Measure Preliminary composite measure from the scales being used in LIFE-DSR

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

LuMind IDSC FoundationLead Sponsor
3 Previous Clinical Trials
92 Total Patients Enrolled
Alzheimer's Disease Cooperative Study (ADCS)OTHER
24 Previous Clinical Trials
6,179 Total Patients Enrolled
Lois KellyStudy DirectorLuMind IDSC Foundation
~40 spots leftby Nov 2025